AXSM - axsome.com Long-Term Liabilities to Capital

Axsome Therapeutics (AXSM) possesses significant pricing power, as patients with severe forms of depression rarely switch from an effective therapy. The current metric stands at 1.74, while the share price visualized below complements the revenue growth data, which remains independent of macroeconomic factors due to patent protection. Axsome Therapeutics (AXSM) is also betting on scientific research, investing in the development of treatments for migraine and Alzheimer's disease.

For an investor in Axsome Therapeutics (AXSM), the balance between R&D capital intensity and financial stability is critical. This long-term debt-to-net assets ratio measures the company's reliance on borrowed funds with maturities exceeding one year, allowing for an assessment of excessive leverage risk. The low burden shown on this chart confirms the effectiveness of a scaling model utilizing contract manufacturing without capital expenditures on plants.